Diagnostics (Jan 2022)

Comparison of FDG PET/CT and Bone Marrow Biopsy Results in Patients with Diffuse Large B Cell Lymphoma with Subgroup Analysis of PET Radiomics

  • Eun Ji Han,
  • Joo Hyun O,
  • Hyukjin Yoon,
  • Seunggyun Ha,
  • Ie Ryung Yoo,
  • Jae Won Min,
  • Joon-Il Choi,
  • Byung-Ock Choi,
  • Gyeongsin Park,
  • Han Hee Lee,
  • Young-Woo Jeon,
  • Gi-June Min,
  • Seok-Goo Cho

DOI
https://doi.org/10.3390/diagnostics12010222
Journal volume & issue
Vol. 12, no. 1
p. 222

Abstract

Read online

Whether FDG PET/CT can replace bone marrow biopsy (BMBx) is undecided in patients with diffuse large B cell lymphoma (DLBCL). We compared the visual PET findings and PET radiomic features, with BMBx results. A total of 328 patients were included; 269 (82%) were PET-negative and 59 (18%) were PET-positive for bone lesions on visual assessment. A fair degree of agreement was present between PET and BMBx findings (ĸ = 0.362, p p = 0.037 for high grey-level zone emphasis; mean 308.8 ± 394.4 versus 135.7 ± 97.2, unadjusted p = 0.048 for short-zone high grey-level emphasis), but statistical significance was not found after multiple comparison correction. Visual FDG PET/CT assessment and BMBx results were discordant in 17% of patients with newly diagnosed DLBCL, and the two tests are complementary in the evaluation of bone involvement.

Keywords